Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05836623 Active, not recruiting - Clinical trials for Advanced and/or Metastatic Solid Tumours

A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions

Start date: December 20, 2022
Phase: Phase 1
Study type: Interventional

CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA) undergoing Phase 1 assessment in patients with PSMA+ solid tumours. This sub study will assess the biodistribution of radiolabelled CB307 in patients with advanced and/or metastatic solid tumours that are PSMA+.

NCT ID: NCT05830539 Active, not recruiting - Clinical trials for Locally Advanced or Metastatic Solid Tumors

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Start date: March 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD and anti-PD-1 in subjects with locally advanced or metastatic solid tumors who have failed or not tolerated to at least first-line system therapy.

NCT ID: NCT05818865 Active, not recruiting - Neoplasm Malignant Clinical Trials

"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.

Start date: January 18, 2021
Phase: N/A
Study type: Interventional

This is multicentric, interventional, non farmacological and prospective study.

NCT ID: NCT05804045 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Start date: April 27, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer are: - Whether the Pimicotinib(ABSK021) works well in patients with TGCT. - Whether the Pimicotinib(ABSK021) is safe in patients with TGCT. Participants will be asked to complete the study procedures: - Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24 weeks in study part 1. - Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. - Receive the administration of Pimicotinib(ABSK021) till study end in study part 3. - Complete the study procedures speficied in the protocol, which is guided by researchers.

NCT ID: NCT05801094 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of QL1604 for Advanced Solid Tumors

Start date: July 20, 2020
Phase: Phase 1
Study type: Interventional

In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.

NCT ID: NCT05790538 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN )

Start date: October 22, 2020
Phase:
Study type: Observational

This study investigates the effects of treatment from chemotherapy for cancer on symptoms, function, and falls during treatment and through the recovery phase of cancer care. The goal is to identify simple tests that can help medical providers predict which and when patients show increased risk for falls and functional decline and informing rehabilitation providers about which mobility deficits to target.

NCT ID: NCT05764915 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors

Start date: February 15, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of RGT-264 as monotherapy in subjects with advanced solid tumors.

NCT ID: NCT05759949 Active, not recruiting - Breast Cancer Clinical Trials

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Start date: March 29, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human, open-label study designed to evaluate the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RLY-5836 in advanced solid tumors in participants harboring a PIK3CA mutation in blood and/or tumor per local assessment. The study consists of 2 parts, a dose escalation (Part 1) and a dose expansion (Part 2).

NCT ID: NCT05757492 Active, not recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Start date: April 26, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous [NSCLC-NS] and Hepatocellular carcinoma [HCC])

NCT ID: NCT05745909 Active, not recruiting - Neoplasms Clinical Trials

Trial Comparing Loop Ileostomy Versus Loop Transverse Colostomy

LIVELOC
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine which stoma creation technique is preferable after low anterior resection of the rectum.